Prasad Manya, Bhardwaj Neha, Gupta Ekta, Thomas Sherin S
Department of Clinical Research and Epidemiology, Institute of Liver and Biliary Sciences, New Delhi, India.
Division of Human Resources for Health, National Health Systems Resource Centre, New Delhi, India.
Euroasian J Hepatogastroenterol. 2024 Jul-Dec;14(2):145-150. doi: 10.5005/jp-journals-10018-1438. Epub 2024 Dec 27.
There is an international consensus among experts advocating for the classification of fatty liver disease as a metabolic condition. However, some authors have raised concerns that this metabolic-centric framing may result in the underdiagnosis of metabolicdysfunction-associated steatotic liver disease (MASLD) in lean individuals. The present study was carried out with the objective of describing metabolic characteristics in MASLD and the prevalence of lean MASLD in the general population.
We carried out a hospital-based cross-sectional study. A pre-tested proforma was used to collect data on socio-demographic factors, lifestyle factors, and medical history. Transient elastography and blood investigations were carried out in all patients. The identification of independent predictors for MASLD and liver fibrosis was carried out using multivariable logistic regression. A test of interaction was conducted for studying effect modification in the association of diabetes and MASLD by subgroups of body mass index (BMI).
A total of 1,243 participants were interviewed and screened for MASLD. The overall prevalence of MASLD was 43.7% ( = 543), with the prevalence of lean MASLD being 4.3% ( = 53). The prevalence of MASLD in lean vs non-lean subjects differed (21.3 vs 66.7%, < 0.001). Of the total MASLD cases, lean MASLD constituted 9.7% of cases. The association of diabetes and MASLD did not differ in subgroups by BMI. The test for interaction to detect effect modification was not statistically significant ( = 0.673).
The results support laying emphasis on metabolic dysfunction as a key criterion when defining fatty liver disease. The findings emphasize the shared metabolic underpinnings between lean and non-lean MASLD and advocate for inclusive approaches in diagnosis, management, and public health initiatives.
Prasad M, Bhardwaj N, Gupta E, Prevalence and Predictors for Lean Fatty Liver Disease in General Population Attending a COVID-19 Vaccination Center in a Tertiary Care Hospital in India. Euroasian J Hepato-Gastroenterol 2024;14(2):145-150.
专家们在国际上达成共识,主张将脂肪性肝病归类为一种代谢性疾病。然而,一些作者担心这种以代谢为中心的框架可能导致对瘦人群体中代谢功能障碍相关脂肪性肝病(MASLD)的漏诊。本研究旨在描述MASLD的代谢特征以及普通人群中瘦型MASLD的患病率。
我们开展了一项基于医院的横断面研究。使用预先测试的表格收集社会人口学因素、生活方式因素和病史数据。对所有患者进行瞬时弹性成像和血液检查。使用多变量逻辑回归确定MASLD和肝纤维化的独立预测因素。通过体重指数(BMI)亚组对糖尿病与MASLD关联中的效应修饰进行交互作用检验。
共对1243名参与者进行了访谈并筛查MASLD。MASLD的总体患病率为43.7%(n = 543),瘦型MASLD的患病率为4.3%(n = 53)。瘦人群体与非瘦人群体中MASLD的患病率不同(21.3%对66.7%,P < 0.001)。在所有MASLD病例中,瘦型MASLD占病例的9.7%。糖尿病与MASLD的关联在BMI亚组中无差异。用于检测效应修饰的交互作用检验无统计学意义(P = 0.673)。
研究结果支持在定义脂肪性肝病时强调代谢功能障碍是关键标准。研究结果强调了瘦型和非瘦型MASLD之间共同的代谢基础,并提倡在诊断、管理和公共卫生举措中采用包容性方法。
Prasad M, Bhardwaj N, Gupta E, 印度一家三级护理医院COVID - 19疫苗接种中心普通人群中瘦型脂肪性肝病的患病率及预测因素。《欧亚肝脏胃肠病学杂志》2024年;14(2):145 - 150。